Trial Profile
Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2012
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Oxycodone (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Purdue Pharma
- 29 Sep 2010 Checked against NCT record.
- 29 Sep 2010 Checked against NCT record.
- 28 Sep 2010 New trial record